PHVS

Pharvaris N.V. 2025 Annual Report (Form 20-F) Summary

Business Context and Reporting Period

Company: Pharvaris N.V.
Reporting Period: Fiscal year ended December 31, 2025.
Business Overview: Pharvaris is a late-stage biopharmaceutical company developing oral therapies for bradykinin-mediated angioedema (AE-BK), specifically Hereditary Angioedema (HAE). The company has no commercial revenue and is focused on the clinical development of its lead product candidate, deucrictibant, in two formulations: an immediate-release (IR) capsule for on-demand treatment and an extended-release (XR) tablet for prophylaxis.
Key Milestone: In December 2025, the company reported positive topline data from the pivotal Phase 3 RAPIDe-3 study for deucrictibant IR. The company plans to submit a New Drug Application (NDA) to the U.S. FDA in the first half of 2026.

Key Financial Metrics (Year Ended Dec 31, 2025)

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by 31% (€41.5 million) compared to 2024, driven primarily by higher R&D expenses and a reversal in foreign exchange results.
• R&D Expense Growth: R&D expenses rose 26% to €124.5 million. This was driven by increased clinical expenses (€67.7 million) and personnel costs (€35.8 million) to support three Phase 3 studies (IR, XR, and AAE). Nonclinical expenses surged 125% due to specific study requirements.
• Foreign Exchange Impact: Finance income turned to expense (€3.9 million loss vs. €13.3 million gain in 2024). This was primarily due to a €19.1 million reduction in the value of U.S. dollar-denominated bank balances as the dollar depreciated approximately 12% against the euro in 2025.
• Capital Raise: In July 2025, the company completed an underwritten offering raising net proceeds of €160.3 million, significantly bolstering liquidity compared to the prior year.
• Reclassifications: Approximately €4.6 million of expenses were reclassified from G&A to R&D to better align with industry practices, though this had no impact on total operating expenses or net loss.

Guidance, Outlook, and Risks

• Regulatory Outlook: Management intends to submit an NDA for deucrictibant IR to the FDA in H1 2026 based on the successful RAPIDe-3 data. The pivotal Phase 3 CHAPTER-3 study for the prophylactic XR formulation is ongoing.
• Liquidity: With €291.7 million in cash as of year-end, management believes funds are sufficient to execute the operating plan for at least 12 months. However, the company expects to continue incurring significant losses and will require additional financing to fund future operations and commercialization.
• Key Risks:
  • Clinical Development: Failure of ongoing trials (XR, AAE) or inability to replicate Phase 2 results in Phase 3.
  • Regulatory: Delays in FDA/EMA approval or requirements for additional studies.
  • Financial: Dependence on equity financing; potential dilution to shareholders; foreign exchange volatility impacting reported results.
  • Manufacturing: Reliance on third-party CDMOs for API and drug product manufacturing.
  • Intellectual Property: Risks related to the license agreement with BRAIN Biotech AG, including potential milestone payments and royalties.

Investor Verification Checklist

• NDA Submission Timeline: Verify the specific date and status of the planned H1 2026 NDA submission for deucrictibant IR.
• Phase 3 XR Progress: Monitor enrollment rates and interim data for the CHAPTER-3 prophylaxis study.
• Cash Burn Rate: Assess the sustainability of the €291.7 million cash balance against the projected €120M+ annual operating cash burn.
• Foreign Exchange Exposure: Review the company's hedging strategy or lack thereof regarding its significant USD cash holdings.
• BRAIN License Obligations: Confirm the status of the €8.0 million in remaining potential milestone payments and royalty structures.
• Commercial Infrastructure: Evaluate the timeline and cost estimates for building the U.S. commercial organization post-approval.